In the context of ongoing discussions around the 2026 PLFSS (Social Security Financing Act Project), this new position paper highlights the current and potential contribution of generics, biosimilars and hybrids to the French healthcare system
These lower-cost drugs:
- Generate substantial savings for the National Health Insurance Fund
- Improve access to treatments for a large number of patients
- Help sustain the economic balance of retail pharmacies
However, the mounting economic pressure faced by manufacturers of these drugs are putting the entire ecosystem at risk, posing a serious threat to all stakeholders involved